SALVAT and Kwang Dong Pharmaceutical Announced Positive Results of Phase IIb for Tarafenacin for Overactive Bladder Treatment
4/10/2013 6:42:51 AM
More...
|
Laboratorios SALVAT, S.A. and WraSer Pharmaceuticals, LLC Announce Exclusive License Agreement for the Commercialization of CETRAXAL(R) (ciprofloxacin otic solution) 0.2%
7/8/2009 11:14:27 AM
More...
|
SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R)
11/6/2008 10:01:10 AM
More...
|
SALVAT Has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
10/10/2007 11:08:29 AM
More...
|
SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776
10/10/2007 7:34:36 AM
More...
|
Chiesi Farmaceutici SpA And SALVAT Sign A Worldwide Development And Licensing Agreement For M3 Muscarinic Receptor Antagonists
1/9/2006 12:30:24 PM
More...
|
SALVAT Seeks FDA Approval For Its CETRAXAL Otic (Ciprofloxacin Otic) 0.2% Solution, For The Treatment Of External Otitis
10/19/2005 5:13:04 PM
More...
|
SALVAT Seeks FDA Approval For its CETRAXAL Otic (ciprofloxacin otic) 0.2% Solution, For The Treatment Of External Otitis
10/19/2005 5:10:58 PM
More...
|
SALVAT Seeks FDA Approval For Its CETRAXAL Otic (ciprofloxacin otic) 0.2% Solution, For The Treatment Of External Otitis
10/19/2005 5:10:20 PM
More...
|
SALVAT Announces The FDA Acceptance Of NDA For Its CETRAXAL Otic Solution
10/19/2005 5:09:20 PM
More...
|
|